drugset / Trial / NCT00203866
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery.
Timeline
- Start
- 2003-10
- Primary completion
- 2007-03
- Completion
- 2007-03
Outcome
Outcome not reported
Stopped: “Study completed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G250 | Unknown | — | — |
| Subject | IL-2 | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |
| Subject | IL-2 | Protein / enzyme biologic | 1.1e+07 iu | Subcutaneous |